Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

RAPT Therapeutics (RAPT) EBITDA Margin: 2020-2022

Historic EBITDA Margin for Therapeutics (RAPT) over the last 2 years, with Jun 2022 value amounting to -2,123.25%.

  • Therapeutics' EBITDA Margin fell 27538.00% to -2,123.25% in Q2 2022 from the same period last year, while for Jun 2022 it was -2,365.04%, marking a year-over-year decrease of 113959.00%. This contributed to the annual value of -5,478.59% for FY2022, which is 366288.00% down from last year.
  • Per Therapeutics' latest filing, its EBITDA Margin stood at -2,123.25% for Q2 2022, which was up 36.34% from -3,335.26% recorded in Q1 2022.
  • In the past 5 years, Therapeutics' EBITDA Margin ranged from a high of -956.70% in Q2 2020 and a low of -3,335.26% during Q1 2022.
  • For the 3-year period, Therapeutics' EBITDA Margin averaged around -1,730.04%, with its median value being -1,627.25% (2020).
  • In the last 5 years, Therapeutics' EBITDA Margin skyrocketed by 5,426bps in 2021 and then plummeted by 198,288bps in 2022.
  • Quarterly analysis of 3 years shows Therapeutics' EBITDA Margin stood at -997.39% in 2020, then plummeted by 140,737bps to -2,404.76% in 2021, then plummeted by 27,538bps to -2,123.25% in 2022.
  • Its last three reported values are -2,123.25% in Q2 2022, -3,335.26% for Q1 2022, and -2,404.76% during Q4 2021.